

BIOMARIN PHARMACEUTICAL INC

Form 8-K

February 10, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 9, 2003

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

000-26727
(Commission
File Number)

68-0397820
(IRS Employer
Identification No.)

371 Bel Marin Keys Boulevard, Suite 210, Novato, California
(Address of principal executive offices)

94949
(Zip Code)

Registrant's telephone number, including area code: (415) 884-6700

Not Applicable

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

(Former name or former address, if changed since last report)

BIOMARIN PHARMACEUTICAL INC.

Item 5. Other Events.

On February 9, 2003, BioMarin Pharmaceutical Inc. (the Registrant) announced financial results for its fourth quarter and the full year ended December 31, 2003. The Registrant's press release issued on February 9, 2003 is attached hereto as Exhibit 99.1 and its audited consolidated financial statements as of December 31, 2002 and for the year ended December 31, 2002 are attached hereto as Exhibit 99.2.

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

(a) *Financial Statements of Business Acquired.*

Not Applicable.

(b) *Pro Forma Financial Information.*

Not Applicable.

(c) *Exhibits.*

Exhibit 23.1	Consent of KPMG LLP
Exhibit 99.1	Press Release of the Registrant dated February 9, 2003
Exhibit 99.2	Audited Consolidated Financial Statements of BioMarin Pharmaceutical Inc. as of December 31, 2002 and for the year ended December 31, 2002

BIOMARIN PHARMACEUTICAL INC.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOMARIN PHARMACEUTICAL INC.,
a Delaware corporation

Date: February 9, 2003

By:

/s/ LOUIS C. DRAPEAU

Louis C. Drapeau

Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 23.1	Consent of KPMG LLP
Exhibit 99.1	Press Release of the Registrant dated February 9, 2003
Exhibit 99.2	Audited Consolidated Financial Statements of BioMarin Pharmaceutical Inc. as of December 31, 2002 and for the year ended December 31, 2002
